回答: 他最起吗还有一次机会.我没有他. 由 xiamai 于 2007-04-12 09:23:00 其实要把握机构对于他的态度是不难的,但是还有没有你说的大机会,谁也不知道。
我为什么在周末推荐买DNDN,因为周五的时候股价再次攀升到18以上(第一天是从18往下扎的最低12),这个时候是明确的作多信号,MM一定要再创新高,而且一般来说都是至少30%-50%的幅度
Dendreon (DNDN) Surges Higher 04-05-2007 01:19:05 PM Dendreon Corp. (Nasdaq: DNDN) is seeing significant upside action (+15%) this afternoon on heavy volume, bringing its 52-week high of $18.05 in play. A short squeeze is suspected.
On March 29, in a surprise move an FDA panel backed the company's PROVENGE for prostate cancer. The Company anticipates a decision from the FDA on PROVENGE by May 15, 2007.
周一如期上涨,周二盘前就已经疯狂张到26了,(高总不想马后炮说是盘前就跑了),18到26就一天时间,40%了,不跑,还等什么呢?但是机构也需要出来放烟雾弹,果然下午MDB置疑FDA会对DNDN的panel推荐真的十分留意,他们为什么机构服务?不知道,但是一定是。
MDB Capital questions whether the FDA will heed the advice of the advisory panel on Dendreon (DNDN) 04-10-2007 02:32:49 PM MDB Capital comments on Dendreon Corp. (Nasdaq: DNDN), questioning whether the FDA will heed the advice of the advisory panel. The firm said, "The recent vote (13 to 4) in favor of Provenge approval by the cellular, tissue and gene therapy advisory panel was a surprise. We believe the FDA will think hard about this one and is probably in a dilemma of sorts. While the FDA normally heeds the decision of its advisory panel, this particular case may not be clear cut." The firm maintains their Neutral rating.
紧接着,昨天早上JMP出来再次downgrade,DNDN股价再次大幅度下滑
JMP Securities downgrades Dendreon (DNDN) to Market Outperform 04-11-2007 09:12:31 AM JMP Securities downgrades momentum mover Dendreon (Nasdaq: DNDN) from Strong Buy to Market Outperform.
昨日盘后又有大量的DNDN如何价值甚至200的豪言,高总实在看不下去了,所以今日在股价低开高走之后,高总在大千预警:DNDN也许就是当年的IPIX。
不要被表象迷惑,5.15之前的表演就是MM的表演。这个时候技术面更为重要。
|